Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role?

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with limited treatment options.
• Autophagy, a cellular degradation process, is implicated in PDAC progression and presents a potential therapeutic target.
• Targeting autophagy offers a novel strategy for PDAC treatment.

Purpose of the Study:

• To develop and utilize a genetically engineered mouse model to study the therapeutic inhibition of autophagy in established PDAC tumors.
• To investigate the efficacy of selectively inhibiting the autophagy gene Atg4b in tumor cells, host cells, or both.

Main Methods:

• Creation of a genetically engineered mouse model to specifically target the autophagy gene Atg4b.
• In vivo studies involving selective inhibition of Atg4b in different cellular compartments within the tumor microenvironment.
• Assessment of tumor growth suppression following autophagy inhibition.

Main Results:

• Selective inhibition of autophagy via Atg4b in tumor cells significantly suppressed tumor growth.
• Inhibition of autophagy in normal host cells also demonstrated a suppressive effect on tumor growth.
• Combined inhibition of autophagy in both tumor and host cells resulted in substantial tumor growth suppression.

Conclusions:

• Targeting autophagy, specifically through Atg4b inhibition, is a viable therapeutic strategy for pancreatic ductal adenocarcinoma.
• The developed mouse model provides a valuable tool for studying autophagy inhibition in PDAC.
• Selective or combined inhibition of autophagy in tumor and host cells can effectively suppress PDAC progression.